Menu Fermer

Publications scientifiques

La maladie de Crigler-Najjar : un nouveau succès pour la thérapie génique

Nicolas Ferry Ancien directeur de recherche à l’Inserm, Paris, France

Med Sci (Paris) 2023 ; 39 : 833–835

https://www.medecinesciences.org/fr/articles/medsci/full_html/2023/10/msc230215/msc230215.html

Article en détail

Gene Therapy in Patients with the Crigler–Najjar Syndrome

Lorenzo D’Antiga, M.D., Ulrich Beuers, M.D., Giuseppe Ronzitti, Ph.D., Nicola Brunetti-Pierri, M.D., Ulrich Baumann, M.D., Angelo Di Giorgio, M.D., Sem Aronson, Ph.D., Aurelie Hubert, Ph.D., Roberta Romano, M.D., Norman Junge, M.D., Piter Bosma, Ph.D., Giulia Bortolussi, Ph.D., Andrés F. Muro, Ph.D., Ravaka F. Soumoudronga, M.D., Philippe Veron, Ph.D., Fanny Collaud, Ph.D., Nathalie Knuchel-Legendre, M.A.Sc., Philippe Labrune, M.D., and Federico Mingozzi, Ph.D.

N Engl J Med 2023; 389:620-631 DOI: 10.1056/NEJMoa2214084 August 17, 2023

https://www.nejm.org/doi/full/10.1056/NEJMoa2214084?query=featured_home

https://pubmed.ncbi.nlm.nih.gov/37585628/

AAV Immunogenicity : New Answers Create New Questions

Jamie L. Shirley, Roland W. Herzog

Volume 26, ISSUE 11, P2538-2539, November 07, 2018

https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(18)30493-3

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

Amine Meliani, Florence Boisgerault, Romain Hardet, Solenne Marmier, Fanny Collaud, Giuseppe Ronzitti, Christian Leborgne, Helena Costa Verdera, Marcelo Simon Sola, Severine Charles, Alban Vignaud, Laetitia van Wittenberghe, Giorgia Manni, Olivier Christophe, Francesca Fallarino, Christopher Roy, Alicia Michaud, Petr Ilyinskii, Takashi Kei Kishimoto & Federico Mingozzi

Nature Communicationsvolume 9, Article number : 4098 (2018)

https://www.nature.com/articles/s41467-018-06621-3

Promoterless gene targeting without nucleases rescues lethality of a Crigler‐Najjar syndrome mouse model

Fabiola Porro, Giulia Bortolussi, Adi Barzel, Alessia De Caneva, Alessandra Iaconcig, Simone Vodret, Lorena Zentilin, Mark A Kay, and Andrés F Muro

EMBO Mol Med. 2017 Oct ; 9(10) : 1346–1355. Published online 2017 Jul 27.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623861/

A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome

Giuseppe Ronzitti, Giulia Bortolussi, Remco van Dijk, Fanny Collaud, Severine Charles, Christian Leborgne, Patrice Vidal, Samia Martin, Bernard Gjata, Marcelo Simon Sola, Laetitia van Wittenberghe, Alban Vignaud, Philippe Veron, Piter J Bosma, Andres F Muro, and Federico Mingozzi

Mol Ther Methods Clin Dev. 2016 ; 3 : 16049. Published online 2016 Jul 20. doi : [10.1038/mtm.2016.49]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052023/

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Nathwani AC1, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM.

N Engl J Med. 2014 Nov 20 ;371(21):1994-2004. doi : 10.1056/NEJMoa1407309.

http://www.ncbi.nlm.nih.gov/pubmed/25409372?dopt=Abstract

Essai clinique de phase I/II en thérapie cellulaire

Promethera Biosciences annonce le démarrage en France de son essai clinique en thérapie cellulaire

Version française  : http://www.france-biotech.org/promethera-biosciences-annonce-le-demarrage-en-france-de-son-essai-clinique-en-therapie-cellulaire/

English version : http://www.news-medical.net/news/20130301/Urea-cycle-disorder-patient-successfully-treated-by-Promethera(R)-HepaStem-in-Phase-III-trial-in-France.aspx

Recommendations for pregnancies in patients with crigler-najjar syndrome.

Wilson JH, Sinaasappel M, Lotgering FK, Langendonk JG.

Departement of internal médicine, internal médicine, metabolic diseases Office D416 Erasmus MC, 2040, 3000 CA, Rotterdam, The Netherlands.

http://www.ncbi.nlm.nih.gov/pubmed/23430496

Ezetimibe : A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia

Montenegro-Miranda PS, Sneitz N, de Waart DR, Ten Bloemendaal L, Duijst S, de Knegt RJ, Beuers U, Finel M, Bosma PJ.

Tytgat Institute for Intestinal and Liver Research, Academic Medical Center of the University of Amsterdam, Meibergdreef 1105BK, Amsterdam, The Netherlands.

http://www.ncbi.nlm.nih.gov/pubmed/22546842

Mycophenolate Mofetil impairs transduction of single-stranded adeno-associated viral vectors.

Montenegro-Miranda P, Ten Bloemendaal L, Kunne C, de Waart DR, Bosma PJ.

Hum Gene Ther. 2011 Jan 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21222531

Correction of Hyperbilirubinemia in Gunn Rats Using Clinically Relevant Low Doses of Helper-Dependent Adenoviral Vectors.

Dimmock D, Brunetti-Pierri N, Palmer DJ, Beaudet AL, Ng P.

Hum Gene Ther. 2011 Feb 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20973621

La Maladie De Crigler Najjar De Type I En Tunisie : Etude de 30 Observations

hajer Aloulou, Afef Ben Thabet, Sonia Khanfir, Lamia Ben Mansour, Imen Chabchoub, Phillipe Labrune, Thouraya Kammoun, Mongia Hachicha

La tunisie Medicale – 2010 ; Vol 88 ( n°010 ) : 707 – 709

http://www.latunisiemedicale.com/article-medicale-tunisie.php?article=1429

Lentiviral vectors that express UGT1A1 in liver and contain miR-142 target sequences normalize hyperbilirubinemia in Gunn rats.

Schmitt F, Remy S, Dariel A, Flageul M, Pichard V, Boni S, Usal C, Myara A, Laplanche S, Anegon I, Labrune P, Podevin G, Ferry N, Nguyen TH.

Gastroenterology. 2010 Sep ;139(3):999-1007, 1007.e1-2. Epub 2010 Jun 19.

http://www.ncbi.nlm.nih.gov/pubmed/20546738

Acceleration of the gastrointestinal transit by polyethylene glycol effectively treats unconjugated hyperbilirubinaemia in Gunn rats.

Cuperus FJ, Iemhoff AA, van der Wulp M, Havinga R, Verkade HJ.

Gut. 2010 Mar ;59(3):373-80. Epub 2009 Nov 5.

http://www.ncbi.nlm.nih.gov/pubmed/19893023

Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease

Kevin A. Strauss, Donna L. Robinson, Hendrik J. Vreman, Erik G. Puffenberger, Graham Hart, D. Holmes Morton

Eur J Pediatr – DOI 10.1007/s00431-005-0055-2 – Received : 29 August 2005 / Accepted : 15 November 2005 © Springer-Verlag 2005

http://xa.yimg.com/kq/groups/8696913/206525069/name/CND_Strauss%20EJP%202006.pdf

Successful pregnancy in a crigler-najjar type I patient treated by phototherapy and semimonthly albumin infusions

GAJDOS Vincent ; PETIT Francois ; TRIOCHE Pascale ; MOLLET-BOUDJEMLINE Alix ; CHAUVEAUD Aurelia ; MYARA Anne ; TRIVIN Francois ; FRANCOUAL Jeanne ; LABRUNE Philippe ;

2006, vol. 131, no3, pp. 921-924 [4 page(s) (article)] Gastroenterology ISSN 0016-5085 CODEN GASTAB

http://cat.inist.fr/?aModele=afficheN&cpsidt=18112628

Prolonged Survival in Three Brothers with Severe Type 2 Crigler-Najjar Syndrome

J.L. Gollan, M.D., M.R.A.C.P., M.R.C.P.**, S.N. Huang, M.D., F.R.C.P.(C) , Barbara Billing, Ph.D., F.R.C.Path.’Correspondence information about the author Ph.D., F.R.C.Path. Barbara Billing , Sheila Sherlock, M.D., F.R.C.P., F.A.C.P.

© 1975 The Williams & Wilkins Company. Published by Elsevier Inc
Gastroentrology : June 1975Volume 68, Issue 6, Pages 1543–1555

http://www.gastrojournal.org/article/S0016-5085(75)80143-0/pdf